US 10,376,508 B2
Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
Igor Gonda, San Francisco, CA (US); James Blanchard, El Granada, CA (US); David C. Cipolla, San Ramon, CA (US); and Luiz Eduardo Moreira Bermudez, Corvallis, OR (US)
Assigned to ARADIGM CORPORATION, Hayward, CA (US); and OREGON STATE UNIVERSITY, Corvallis, CA (US)
Filed by ARADIGM CORPORATION, Hayward, CA (US); and OREGON STATE UNIVERSITY, Corvallis, OR (US)
Filed on Nov. 22, 2017, as Appl. No. 15/821,193.
Application 15/362,405 is a division of application No. 14/675,218, filed on Mar. 31, 2015, granted, now 9,532,986, issued on Jan. 3, 2017.
Application 15/821,193 is a continuation of application No. 15/362,405, filed on Nov. 28, 2016, granted, now 9,844,548.
Claims priority of provisional application 61/976,727, filed on Apr. 8, 2014.
Prior Publication US 2018/0092912 A1, Apr. 5, 2018
Int. Cl. A61K 31/496 (2006.01); A61K 9/127 (2006.01); A61K 9/00 (2006.01); A61K 9/12 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 9/0078 (2013.01); A61K 9/12 (2013.01); A61K 9/127 (2013.01); A61K 45/06 (2013.01); A61K 9/0073 (2013.01); Y02A 50/404 (2018.01)] 16 Claims
OG exemplary drawing
 
1. A method of treating an antibiotic resistant infection in a patient, comprising:
aerosolizing a formulation comprising free ciprofloxacin and ciprofloxacin encapsulated in liposomes; and
inhaling the aerosol into the patient's lungs whereby 90% or more of the liposomes maintain structural integrity after being aerosolized and after contacting lung tissue provide a ciprofloxacin release rate of 0.5% to 10% per hour,
wherein the antibiotic resistant infection comprises microorganisms in a biofilm in the lung of the patient and the liposomes release drug over a period of time and at a rate effective in treating a biofilm infection;
wherein the liposomes comprise a cryopreservative and a surfactant and have an average particle size of about 75 nm to about 120 nm and are unilamellar.